9900253-7
IPOS

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/58, 31/57, 31/565	A1	(11) International Publication Number: WO 98/04269
		(43) International Publication Date: 5 February 1998 (05.02.98)

(21) International Application Number: PCT/US97/12795

(22) International Filing Date: 23 July 1997 (23.07.97)

(30) Priority Data:
08/686,790 26 July 1996 (26.07.96) US

(71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).

(72) Inventor: GAST, Michael, Jay; 230 Country Lane, Phoenixville, PA 19460 (US).

(74) Agents: ALICE, Ronald, W.; American Home Products Corporation, Patent Law Dept. - 2B, One Campus Drive, Parsippany, NJ 07054 (US) et al.

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: MONOPHASIC CONTRACEPTIVE METHOD AND KIT COMPRISING A COMBINATION OF A PROGESTIN AND ESTROGEN

(57) Abstract

This invention provides a method of contraception which comprises administering to a female of child bearing age for a combination of a progestin at a daily dosage of 40-500 μg trimegestone, 250 μg - 4 mg dienogest, or 250 μg - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 μg ethinyl estradiol for 23-25 days beginning on day 1 of the menstrual cycle, and wherein the same dosage of the progestin and estrogen combination is administered in each of the 23-25 days.